Working… Menu
Help guide our efforts to modernize
Send us your comments by March 14, 2020.

The Efficacy and Safety of Lenalidomide Monotherapy in Red Blood Cell Transfusion Dependent Subjects With Myelodysplastic Syndrome (MDS) Associated With Del (5q) Abnormality

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00874978
Recruitment Status : Completed
First Posted : April 3, 2009
Last Update Posted : February 27, 2019
Information provided by:
King's College Hospital NHS Trust

Brief Summary:
The purpose of this study is to evaluate the efficacy of lenalidomide treatments to achieve haematopoietic improvement in subjects with low- or intermediate-1 risk International Prognostic Scoring System1 (IPSS) myelodysplastic syndrome (MDS) associated with a del (5q31-33) cytogenetic abnormality.

Condition or disease Intervention/treatment Phase
Myelodysplastic Syndromes Drug: lenalidomide Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 36 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: The Efficacy and Safety of Lenalidomide (Revlimid®) Monotherapy in Red Blood Cell Transfusion Dependent Subjects With Myelodysplastic Syndrome Associated With Del (5q) Cytogenetic Abnormality
Study Start Date : January 2005
Actual Primary Completion Date : May 2016
Actual Study Completion Date : May 2016

Arm Intervention/treatment
Experimental: lenalidomide Drug: lenalidomide
Oral lenalidomide 10mg (two 5mg capsules) daily on days 1-21 every 28 days for up to 6 cycles.
Other Names:
  • Revlimid
  • CC-5013

Primary Outcome Measures :
  1. Red blood cell (RBC) transfusion independence. [ Time Frame: monthly ]

Secondary Outcome Measures :
  1. Cytogenetic response [ Time Frame: 3, 6 and 12 months ]
  2. Over or equal to 50% decrease in RBC transfusion requirements [ Time Frame: monthly ]
  3. Change of haemoglobin concentration from baseline [ Time Frame: every 2 and 4 weeks ]
  4. Safety (type, frequency, severity, and relationship of adverse events to lenalidomide) [ Time Frame: monthly ]
  5. Platelet response [ Time Frame: every 2 and 4 weeks ]
  6. Neutrophil response [ Time Frame: every 2 and 4 weeks ]
  7. Bone marrow response [ Time Frame: 3, 6 and 12 months ]
  8. Duration of response [ Time Frame: monthly ]
  9. Gene expression profiling of patients with the 5q- syndrome and effects of lenalidomide on gene expression profiles [ Time Frame: 3, 6 and 12 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Understand and voluntarily sign an informed consent form.
  2. Age over or equal to 18 years at the time of signing the informed consent form.
  3. Able to adhere to the study visit schedule and other protocol requirements.
  4. Diagnosis of low- or intermediate-1-risk (IPSS) MDS associated with a del(5q) cytogenetic abnormality. The cytogenetic abnormality of chromosome 5 must involve a deletion between bands q31 and q33. The del(5q) cytogenetic abnormality may be an isolated finding or may be associated with other cytogenetic abnormalities.
  5. RBC transfusion-dependent anaemia defined as having no transfusion free interval of < 56 consecutive days within the past 112 days.
  6. Eastern Cooperative Oncology Group (ECOG) performance status score of 0, 1, or 2.
  7. Women of childbearing potential (WCBP)† must have a negative serum or urine pregnancy test with a sensitivity of at least 50 mIU/mL 10 - 14 days prior to therapy and repeated within 24 hours of starting study drug and must either commit to continued abstinence from heterosexual intercourse or begin TWO acceptable methods of birth control, one highly effective method and one additional effective method AT THE SAME TIME, at least 4 weeks before she starts taking lenalidomide. Women must also agree to ongoing pregnancy testing. Men must agree not to father a child and agree to use a condom if his partner is of child bearing potential.
  8. Laboratory test results within these ranges:

    • Absolute neutrophil count over or equal to 0.5 x 109/L
    • Platelet count over or equal to 25 x 109/L
    • Serum creatinine under or equal to 2.0 mg/dl
    • Total bilirubin under or equal to 1.5 mg/dl
    • AST (SGOT) and ALT (SGPT) under or equal to 3 x ULN.
  9. Disease free of prior malignancies for over or equal to 5 years with exception of currently treated basal cell, squamous cell carcinoma of the skin, or carcinoma "in-situ" of the cervix or breast.

Exclusion Criteria:

  1. Any serious medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from signing the informed consent form.
  2. Pregnant or lactating females.
  3. Prior > grade 3 (National Cancer Institute [NCI] Common Toxicity Criteria [CTC]) allergic reaction to thalidomide.
  4. Prior > grade 3 (NCI CTC) rash or any desquamation (blistering) while taking thalidomide.
  5. Clinically significant anaemia due to factors such as iron, B12 or folate deficiencies,autoimmune or hereditary haemolysis or gastrointestinal bleeding (if a marrow aspirate is not evaluable for storage iron, transferrin saturation must be > 20 % and serum ferritin not less than 50 ng/ml).
  6. Use of haematopoietic growth factors within 7 days of the first day of study drug treatment. Use of G-CSF is permitted.
  7. Concurrent use of erythropoietin
  8. Chronic use (>2 weeks) of greater than physiologic doses of a corticosteroid agent (dose equivalent to >10 mg/day of prednisolone) within 28 days of the first day of study lenalidomide treatment.
  9. Use of experimental or standard drugs (i.e. chemotherapeutic, immunosuppressive, and cytoprotective agents) for the treatment of MDS within 28 days of the first day of study lenalidomide treatment.
  10. Prior history of malignancy other than MDS (except basal cell or squamous cell carcinoma or carcinoma in situ of the cervix or breast) unless the subject has been free of disease for >3 years.
  11. Any prior use of lenalidomide.
  12. Concurrent use of other anti-cancer agents or treatments. Patients must not have received any form of chemotherapy for at least 4 weeks prior to study entry and must have fully recovered from haematological toxicity associated with this therapy.
  13. Known positive for HIV or infectious hepatitis, type A, B or C.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00874978

Layout table for location information
United Kingdom
King's College Hospital NHS Foundation Trust
London, United Kingdom, SE5 9RS
Sponsors and Collaborators
King's College Hospital NHS Trust
Layout table for investigator information
Principal Investigator: Ghulam J Mufti, MB, DM, FRCP, FRCPath King's College London

Layout table for additonal information
Responsible Party: Professor Ghulam Mufti, King's College London Identifier: NCT00874978    
Other Study ID Numbers: 04CC06
REC - 04/Q0703/148
EudraCT - 2004-005101-29
First Posted: April 3, 2009    Key Record Dates
Last Update Posted: February 27, 2019
Last Verified: September 2015
Keywords provided by King's College Hospital NHS Trust:
myelodysplastic syndromes
Additional relevant MeSH terms:
Layout table for MeSH terms
Myelodysplastic Syndromes
Pathologic Processes
Bone Marrow Diseases
Hematologic Diseases
Precancerous Conditions
Immunologic Factors
Physiological Effects of Drugs
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Growth Inhibitors
Antineoplastic Agents